Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06569147 · ClinicalTrials.gov registry record · Phase 1
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
A Phase 1 study of AL Amyloidosis, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT06569147 is a Phase 1 study of AL Amyloidosis that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 49 participants, below the 421-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06569147, a Phase 1 study of AL Amyloidosis, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis.
Conditions Studied
Interventions
- DRUG Elranatamab
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2029-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06569147
The ClinicalTrials.gov registry entry for NCT06569147 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 421-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (88% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with AL Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which Elranatamab is the first listed.
NCT06569147 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06569147 about?
NCT06569147 is a clinical study titled "Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis". This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis.
What is the current status of trial NCT06569147?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2024-11-01. Estimated completion is 2029-09-01.
What conditions does trial NCT06569147 study?
This clinical trial studies the following conditions: AL Amyloidosis.
What interventions are being tested in trial NCT06569147?
The interventions under investigation include: Elranatamab (DRUG).
Who is sponsoring clinical trial NCT06569147?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06569147 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AL Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
RECRUITING · Phase 1
-
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
ACTIVE NOT RECRUITING · Phase 1
-
Radioimmunoimaging of AL Amyloidosis
COMPLETED · Phase 1
-
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RECRUITING
-
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.